Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01470599 · ClinicalTrials.gov registry record · Phase 2

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target

NCT01470599 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01470599, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target

Study Summary

The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.

Interventions

  • DRUG CP-690,550

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2012-04
Est. Completion 2016-07
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01470599

The ClinicalTrials.gov registry entry for NCT01470599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which CP-690,550 is the first listed.

NCT01470599 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01470599 about?

NCT01470599 is a clinical study titled "A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease". The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.

What is the current status of trial NCT01470599?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2012-04. Estimated completion is 2016-07.

What interventions are being tested in trial NCT01470599?

The interventions under investigation include: CP-690,550 (DRUG).

Who is sponsoring clinical trial NCT01470599?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.